Genomics applied to the treatment of breast cancer

Diaddin Hamdan; Thi Thuy Nguyen; Christophe Leboeuf; Solveig Meles; Anne Janin; Guilhem Bousquet

doi:10.18632/oncotarget.27102

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Genomics applied to the treatment of breast cancer

Diaddin Hamdan, Thi Thuy Nguyen, Christophe Leboeuf, Solveig Meles, Anne Janin and Guilhem Bousquet _

PDF | Full Text | How to cite

Oncotarget. 2019; 10:4786-4801. https://doi.org/10.18632/oncotarget.27102

Metrics: PDF 1717 views | Full Text 2762 views | ?

Abstract

Diaddin Hamdan1^,2, Thi Thuy Nguyen2^,3^,4, Christophe Leboeuf2^,5, Solveig Meles2, Anne Janin2^,5^,* and Guilhem Bousquet2^,6^,7^,*

1 Hôpital La Porte Verte, Versailles F-78004, France

2 U942, Université Paris-Diderot, INSERM, Paris F-75010, France

3 National Cancer Hospital, Medical Oncology Department 2, Ha Noi 110000, Viet Nam

4 Ha Noi Medical University, Oncology Department, Ha Noi 116001, Viet Nam

5 AP-HP-Hôpital Saint-Louis, Laboratoire de Pathologie, Paris F-75010, France

6 AP-HP-Hôpital Avicenne, Service d’Oncologie Médicale, Bobigny F-93000, France

7 Université Paris 13, Leonard de Vinci, Villetaneuse F-93430, France

* These authors contributed equally to this work

Correspondence to:

Guilhem Bousquet,

email:

[email protected]

Keywords: constitutional genomics; genomics applied to treatment; genomics of breast cancer; molecular and histological classification; tumor heterogeneity

Received: March 18, 2019 Accepted: July 05, 2019 Published: July 30, 2019

ABSTRACT

Breast cancer remains a major health issue in the world with 1.7 million new cases in 2012 worldwide. It is the second cause of death from cancer in western countries. Genomics have started to modify the treatment of breast cancer, and the developments should become more and more significant, especially in the present era of treatment personalization and with the implementation of new technologies. With molecular signatures, genomics enabled a de-escalation of chemotherapy and personalized treatments of localized forms of estrogen-dependent breast cancers. Genomics can also make a real contribution to constitutional genetics, so as to identify mutations in a panel of candidate genes. In this review, we will discuss the contributions of genomics applied to the treatment of breast cancer, whether already validated contributions or possible future applications linked to research data.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 27102

Publication Alerts

Reviews:

Genomics applied to the treatment of breast cancer

Abstract